Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohnʼs disease

医学 安慰剂 胃肠病学 内科学 克罗恩病 临床终点 安慰剂对照研究 胰高血糖素样肽-2 随机对照试验 疾病 双盲 肽 病理 生物化学 化学 替代医学
作者
Alan L. Buchman,Seymour Katz,John C. Fang,Charles Noah Bernstein,Souheil G. Abou‐Assi
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
卷期号:16 (6): 962-973 被引量:154
标识
DOI:10.1002/ibd.21117
摘要

BACKGROUND: Teduglutide, an analog of glucagon-like peptide-2 (GLP-2), is associated with trophic effects on gut mucosa. Its role in the treatment of active Crohn's disease (CD) was assessed in a pilot, randomized, placebo-controlled, double-blinded, dose-ranging study. METHODS: Subjects with moderate-to-severe CD were randomized 1:1:1:1 to placebo or 1 of 3 doses of teduglutide (0.05, 0.10, or 0.20 mg/kg daily) delivered as a daily subcutaneous injection for 8 weeks. The primary outcome measure was the percentage of subjects in each group that responded to treatment, defined as a decrease in Crohn's Disease Activity Index (CDAI) score to <150 or a decrease of > 100 points. At week 8 there was an optional 12-week open-label period of treatment with teduglutide 0.10 mg/kg/d. RESULTS: One hundred subjects were enrolled and 71 completed the study. The mean baseline CDAI score was 290.8 +/- 57.6 and was similar across groups. There were numerically higher response and remission rates in all teduglutide-treated groups as compared with placebo, although the percentage of subjects who achieved a clinical response or remission was more substantial, and seen as early as week 2 of treatment in the highest dose (0.2 mg/kg/d) group (44% response and 32% remission versus 32% response and 20% remission in the placebo group). Of subjects who had not achieved remission during the 8-week placebo-controlled phase in the higher-dose group, 50% achieved remission during the more prolonged, open-label treatment phase. Plasma citrulline was similar across groups at baseline, but increased substantially over time in all teduglutide groups when compared with placebo at week 8. Adverse events were not different between placebo and active treatment groups. CONCLUSIONS: Teduglutide is a novel and potentially effective therapy for inducing remission and mucosal healing in patients with active moderate-to-severe CD. Further clinical investigation of this growth factor is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
阔达的心情完成签到,获得积分10
1秒前
1秒前
哭嘻嘻发布了新的文献求助10
2秒前
3秒前
4秒前
lawang发布了新的文献求助10
4秒前
lx完成签到,获得积分10
4秒前
好好学习呀完成签到,获得积分10
5秒前
mimilv完成签到,获得积分10
9秒前
CipherSage的应助被牙牙乐采纳,获得10
9秒前
科研小白发布了新的文献求助30
9秒前
9秒前
Gyz发布了新的文献求助10
9秒前
秦院长完成签到,获得积分10
10秒前
科研通AI6.4的应助被里大炮采纳,获得10
10秒前
田様的应助被谦让如冰采纳,获得10
11秒前
liuyi发布了新的文献求助10
11秒前
12秒前
13秒前
chencc完成签到,获得积分10
14秒前
15秒前
houbowen完成签到,获得积分10
15秒前
coast完成签到 ,获得积分10
15秒前
幸福的电话完成签到,获得积分10
15秒前
GGBong完成签到,获得积分10
16秒前
碧蓝梦寒完成签到,获得积分10
16秒前
ask你回家完成签到,获得积分10
17秒前
无极微光的应助被lx采纳,获得20
17秒前
WYP发布了新的文献求助10
17秒前
17秒前
大阪女中音完成签到,获得积分20
17秒前
zsl完成签到,获得积分10
18秒前
独云完成签到,获得积分10
19秒前
Jun的应助被嘟哒哒采纳,获得10
19秒前
20秒前
wei发布了新的文献求助10
20秒前
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191571
求助须知:如何正确求助?哪些是违规求助? 9578332
关于积分的说明 21858634
捐赠科研通 7790907
什么是DOI,文献DOI怎么找? 3436656
关于科研通互助平台的介绍 2560375
邀请新用户注册赠送积分活动 2483446